A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients With Advanced High-Grade Osteosarcoma	Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, connective tissue neoplasm, neoplasm, osteosarcoma, sarcoma	Recruiting	Phase 2	2025-01-10		NCT06650514

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Curing Kids' Cancer Foundation	2
Dana-Farber Cancer Institute	324
Memorial Sloan Kettering Cancer Center	753
Oregon Health and Science University	244
Osteosarcoma Institute	2
Peptomyc S.L.	3
The Kristen Ann Carr Fund	1
The Morgan Adams Foundation	1
Vall d'Hebron Institute of Oncology	18

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Hospital Universitari Vall d'Hebron	Barcelona	Spain	200